The manufacturer hoped for an approval date of November 2020, but the COVID-19 pandemic and a June 2021 inspection that discovered quality control and cell bank problems delayed the process.
The drug, which is delivered by injection, reduces the appearance of facial wrinkles for about six months. Mark Foley, CEO of Revance Therapeutics, told The New York Times Sept. 8 that the company spent many years trying to discover an “effective neuromuscular blocking agent” that could be applied without a needle and found that peptide technology kept the formula stable.
“It also opens up the door for what we can do with therapeutics,” Mr. Foley said. “If you think of migraines, cervical dystonia, overactive bladder, there’s a huge medical opportunity as well.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
